Get to know our clinical trials
Study to evaluate the safety, pharmacokinetics and efficacy of ABBV-400 in adult subjects with advanced solid tumors
THE PURPOSE OF THIS STUDY IS TO SEE IF ABBV-400, THE STUDY DRUG, IS SAFE, TO DETERMINE SAFE DOSES OF ABBV-400, TO LOOK AT THE AMOUNT OF ABBV-400 PRESENT IN THE BLOOD AT VARIOUS TIMES (TESTS KNOWN AS "PHARMACOKINETICS"), AND TO DETERMINE IF TREATMENT WITH ABBV-400 HAS AN EFFECT ON VARIOUS TYPES OF CANCER. THIS STUDY IS FOR PATIENTS WITH ADVANCED SOLID TUMORS AND IN COLORECTAL CANCER, GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, AND NON-SMALL CELL LUNG CANCER THAT HAVE RECURRED OR ARE RESISTANT, MEANING THEY HAVE RECURRED, GROWN LARGER, OR PROGRESSED DURING OR AFTER ONE OR MORE PREVIOUS TREATMENTS.
Technical Summary
- PHASE 1, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV-400 IN ADULT SUBJECTS WITH ADVANCED SOLID TUMORS
- Code EudraCT: 2021-002258-98
- Protocol number: M21-404
- Promoter: Abbvie Spain SLU
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.